Matthew Fowler

Stephanie White, DO, and Preeti Kotha, PharmD, detailed their experiences running the WesternU Health Clinic COVID-19 vaccine program from when vaccines were first approved in the United States until now.

Data from the phase 3 TULIP trial showed that [vic-]trastuzumab duocarmazine yielded positive progression-free survival for patients with pretreated HER2-positive metastatic breast cancer.

This special edition of the “Oncology Peer Review On-The-Go” podcast hosts Mark Socinski, MD, who discusses important factors in treating and managing extensive-stage small cell lung cancer, and details information from the IMpower133 trial.

Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

For the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® sat down with Gilles Salles, MD, to discuss different treatment regimens for transplant-ineligible DLBCL in this special edition episode.

Ixazomib plus daratumumab and low-dose dexamethasone yielded a high response rate and improved quality of life in frail patients with newly diagnosed multiple myeloma.

The results of a randomized control trial emphasized the need for screening methods earlier in disease but did not show a reduction in deaths for patients with ovarian and tubal cancer.

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.

CancerNetwork® dissects an article from the journal ONCOLOGY® focusing on academic and community molecular profiling practices for patients with pancreatic adenocarcinoma.

Here are some of the important updates from last week you might have missed, including data from the 2021 ASCO Annual Meeting.

This special edition of the “Oncology Peer Review On-The-Go” podcast details treatment options and considerations for relapsed/refractory follicular lymphoma.

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.

Look at some of the important updates from last week you might have missed from the 2021 ASCO Annual Meeting and the FDA.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel significantly improved outcomes for patients with relapsed or refractory multiple myeloma when compared with conventional therapies.

The standard of care cohort comprised of patients across 3 global trials acted as a comparator for treatment with cilta-cel in patients with triple-class exposed multiple myeloma.

Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.

Look back at some of the important news and notes from last week you might have missed in the world of oncology from the 2021 ASCO Annual Meeting, the FDA, and the journal ONCOLOGY®.

CancerNetwork® spoke with 2 experts to learn more about focal therapy and its role in treating localized prostate cancer moving forward.

The combination treatment produced complete responses in more than half of the patients included in the phase 2 CAPTIVATE study.

Median progression-free and overall survival in patients with CLL/SLL receiving ibrutinib in the frontline still not reached at 7-year follow-up, according to data from RESONATE-2 trial reported at the 2021 ASCO Annual Meeting.

According to new research, patients with chronic lymphocytic leukemia may have suboptimal antibody-mediated response with COVID-19 vaccination.

The results from a retrospective trial that found stereotactic radiosurgery produced comparable results for both brainstem metastases and nonbrainstem brain metastases suggest both groups of patients should be eligible for stereotactic radiosurgery clinical trials.

The priority review designation for pacritinib is based off results from 3 trials investigating pacritinib 200 mg twice daily for patients with myelofibrosis and severe thrombocytopenia.

Look back at some of the important news and notes from last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY®.

A 3-year follow-up analysis of event-free and overall survival revealed similar results for patients with stage II or III ERBB2-positive breast cancer treated with either neoadjuvant anthracycline and nonanthracycline treatment regimens.

The phase 1/2a trial reported favorable efficacy data in the first-line setting when compared with existing historical results for treating advanced pancreatic cancer.

Two posters on the efficacy of trilaciclib for treating myelosuppression were presented at the Virtual International Society for Pharmacoeconomics and Outcomes Research 2021.

A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.

The approval of 18F-DCFPyL comes on the heels of positive results from the company-sponsored research in the CONDOR and OSPREY trials investigating the imaging agent for prostate cancer.

Recently announced phase 3 data show similar progression-free survival results between melflufen and pomalidomide, the most used medicine for patients with relapsed or refractory multiple myeloma.